A large retrospective cohort analysis involving patients with T2D receiving insulin, across 85 healthcare organizations, evaluated the effect of SGLT2-I, GLP-1RA, and combination therapy on clinical outcomes [12]. The gene discussed is INS; the disease is type 2 diabetes mellitus.